In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic fragment AOD-9604 | Conjugate Dulaglutide (Trulicity) | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic fragment | Conjugate | |
| Area | Weight and metabolic | Weight and metabolic | |
| Evidence | |||
| Amount of evidence | 44 | 1,919 | |
| Evidence level | Results from animal studies onlyRegistered trials, no results from human studies | Has results from studies in people | |
| Safety | |||
| Safety results | 3 (0 in people) | 488 (445 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 3 | 124 · 15 active19 more mention it but do not test it | |
Shared outcomes
From the regulatory data of each peptide.
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 8 Oct 2026).
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | AOD-9604 | Dulaglutide (Trulicity) |
|---|---|---|
| Glycemic controlMetabolic and weight | 33 | 564537261 |
| Body weight |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The FDA label for Trulicity says: “A GLP-1 analog fused to an IgG4 Fc region, approved for type 2 diabetes and specified cardiovascular risk reduction”
55 |
1781726 |
| Inflammation markersImmune and inflammation | 11 | 6822451 |
|---|
| Receptor activity and mechanismPharmacology | 624 | 70114118 |
|---|
| MortalityInfection | 11 | 2323 |
|---|
| Body compositionMetabolic and weight | 11 | 1111 |
|---|
| Immune responseImmune and inflammation | 11 | 208111 |
|---|
| Bone and jointMusculoskeletal | 66 | 44 |
|---|
| PainNervous system and cognition | 963 | 11 |
|---|
| Cell viability and deathInfection | 11 | 55 |
|---|
| Infection and antimicrobial activityInfection | 22 | 11 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
AOD-9604 differs from Somatotropin (human growth hormone) at 1 position and carries 1 added group.
What is different
Dulaglutide (Trulicity) differs from GLP-1 (7-37) at 246 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
The other peptides have no randomized result on the same measure, so these results cannot be set side by side.
| Outcome | AOD-9604 | Dulaglutide (Trulicity) |
|---|---|---|
| Glycemic controlMetabolic and weightCompared as: difference from placebo, in % | No randomized trial result 3 results from other study designs. | −1% HbA1c change difference Dose studied: 1.5 mg once weekly28 weeksn = 2912023 |
| Body weightMetabolic and weightCompared as: difference from placebo, in kg | No randomized trial result 5 results from other study designs. | −2.9 kg Baseline-adjusted difference in weight change Dose studied: 1.5 mg once weekly12 weeksn = 2552023 |
| Receptor activity and mechanismEndocrine and hormonesCompared as: difference from placebo, in pmol/l | No randomized trial result 6 results from other study designs. | −0.7 pmol/L Median within-subject copeptin difference Dose studied: 1.5 mg once weekly3 weeksn = 542026 |
| MortalityWhole bodyCompared as: value in the arm that got the peptide, in % | No randomized trial result 1 result from other study designs. | 10.8% Mortality Placebo: 12% Dose studied: 1.5 mg weeklyMedian follow-up 5.4 yearsn = 9,9012019 |
No randomized trial result
3 results from other study designs.
−1%
HbA1c change difference
Dose studied: 1.5 mg once weekly28 weeksn = 2912023
No randomized trial result
5 results from other study designs.
−2.9 kg
Baseline-adjusted difference in weight change
Dose studied: 1.5 mg once weekly12 weeksn = 2552023
No randomized trial result
6 results from other study designs.
−0.7 pmol/L
Median within-subject copeptin difference
Dose studied: 1.5 mg once weekly3 weeksn = 542026
No randomized trial result
1 result from other study designs.
10.8%
Mortality
Placebo: 12%
Dose studied: 1.5 mg weeklyMedian follow-up 5.4 yearsn = 9,9012019
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
3 trials · 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Lateral Pharma Pty Ltd53 participants9 Apr 2019 to 3 May 2020
Neuropathic Pain · Diabetic Peripheral Neuropathy (DPN) · Post Herpetic Neuralgia (PHN)
Lateral Pharma Pty Ltd21 participants24 Sept 2019 to 10 Apr 2020
Acute Migraine
Lateral Pharma Pty Ltd26 participants17 May 2022 to 16 Jun 2023
Radiculopathy Lumbar
Top 3 of 124 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Eli Lilly and Company13,299 participants29 May 2020 to 12 Jun 2025
Type 2 Diabetes Mellitus
Eli Lilly and Company9,901 participants22 Jul 2011 to 21 Aug 2018
Cardiovascular Disease · Diabetes Mellitus, Type 2
Eli Lilly and Company1,842 participants5 Apr 2018 to 10 Oct 2019
Diabetes Mellitus, Type 2
19 more mention it but do not test it. They only measure it or name it in their text.